OSS, Netherlands, June 2 /PRNewswire/ -- Organon, the human healthcare business unit of Akzo Nobel, continues to innovate within anesthesia through its research and development program and by working in close partnership with anesthesiology professionals.
The European Society of Anesthesiologists’ annual congress (Euroanaesthesia 2006) currently taking place in Madrid, Spain and the World Congress for Nurse Anesthetists starting later this week in Lausanne, Switzerland are the ideal platforms to continue to show the commitment of Organon to anesthesia and meet with the anesthesia professionals.
“Organon has a long history in the development and marketing of innovative products that support anesthesiologists and contribute to patient care. We recognize the achievements of anesthesiologists, the importance and complexity of the work they do and remain committed to continuing to meet their needs through development of innovative solutions that assist them in caring for their patients,” said Ron Riegman, Vice President, Global Franchise Lead Anesthesia.
In more than 40 years of anesthesia research and development together with anesthesiology professionals, Organon has introduced several innovative products into clinical practice, including Esmeron(R) the fast-onset muscle relaxant. First available in 1994, it has been used in over 125 million patients worldwide and remains one of the most widely used muscle relaxants in the global anesthesia market. Prior to Esmeron, Organon introduced Norcuron(R) in 1983, which at the time was considered a significant advance in neuromuscular blockade.
As well as providing innovative products for anesthesiologists, Organon continues to support several educational CME (Continuing Medical Education) activities via educational grants. Organon also supports AnesthesiaNow.com with an educational grant. This website is a valuable online professional information service for anesthesiology professionals around the world. The independent advisory board to this website announced this week that it had attracted more than 10,000 subscribers less than one year since launch.
Riegman said that during both congresses the new Organon Anesthesia identity will be rolled out and that its main congress sponsorships illustrate the company’s ongoing commitment to this area as well as the study of sugammadex which is currently in phase III trials.
“This study product exemplifies the innovative approach that Organon takes and is continuing to take in the area of anesthesiology. The company has built up strong expertise in this area and is strongly committed to the introduction of future innovations,” added Herm Cukier, Executive Vice President of Global Marketing and Global Venture Teams.
About Organon
Organon -- with shared head offices in Roseland, N.J., USA and Oss, The Netherlands -- creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: gynecology, fertility, neuroscience and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.
For further information, please visit http://www.organon.com.
Safe Harbor Statement*
This report contains statements which address such key issues as Organon’s growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the “Outlook,” should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more complete discussion of the risk factors affecting our business please see the Akzo Nobel Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company’s website http://www.akzonobel.com.
* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.
Organon
CONTACT: Monique Mols, Director, Media Relations, of Organon,+31-412-66-54-40, or monique.mols@organon.com
